Download PDFPDF
Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Clinical use of paraneoplastic antibodies

    Dear Editor

    How useful is antibody testing for paraneoplastic disease in a patient without known tumour?

    Dr Rees proposes to search for paraneuroplastic antibodies in patients with possible paraneoplastic syndromes. At the same time he points out that the incidence of specific disabling neurological paraneoplastic syndromes is very low. No information on the sensitivity and specifity of an antibody scre...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Re: Clinical use of paraneoplastic antibodies

    Dear Editor

    Dr Grueger raises an interesting and relevant management point about the usefulness or not of testing patients with suspected paraneoplastic neurological disease for the presence of anti-neuronal antibodies.

    I do not agree however that this test has no benefit. These antibodies are highly specific for an underlying tumour e.g. anti-Hu for small cell lung cancer and anti-Yo for breast and gy...

    Show More
    Conflict of Interest:
    None declared.